VertexNASDAQ: VERX

Vertex (VERX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Vertex (VERX) possesses solid growth attributes, which could help it handily outperform the market.

Does Vertex (VERX) have what it takes to be a top stock pick for momentum investors? Let's find out.

The headline numbers for Vertex (VERX) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Vertex (VERX) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.10 per share a year ago.

Vertex reported strong Q3 results driven by the growth of the cystic fibrosis franchise and raised the full-year revenue guidance range by $100 million at the mid-point. Casgevy finally generated commercial revenue in Q3 and Vertex continues to work in the background to get treatment centers up and running and patients treated. The VX-880 clinical program is progressing to the pivotal stage and povetacicept generated promising data in membranous nephropathy patients.

VRTX's revenues in the third quarter of 2024 are likely to have been driven by the robust sales of its lead CF product, Trikafta/Kaftrio.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today provided updates on multiple kidney diseases in its pipeline including IgA nephropathy (IgAN), primary membranous nephropathy (pMN), and APOL1-mediated kidney disease (AMKD). These updates demonstrate the transformative potential of Vertex's investigational therapies in multiple serious kidney diseases, and include positive new data on povetacicept, a dual inhibitor of the BAFF and APRIL pathways, in IgAN and pMN,.

Its latest report of clinical data suggests it has a winner on its hands.